

**COMMONWEALTH OF KENTUCKY  
CABINET FOR HEALTH AND FAMILY SERVICES  
DEPARTMENT FOR MEDICAID SERVICES  
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

**NOTE: This meeting will be held virtually via Zoom webinar.**

Thursday, September 17, 2020  
1:00 P.M. to 4:00 P.M. (Eastern)

**Access Information**

Smartphone/Web	Dial-In
<a href="https://magellanhealth.zoom.us/j/93047561955">https://magellanhealth.zoom.us/j/93047561955</a> Webinar ID: 930 4756 1955 Password: AUXNP0	+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 930 4756 1955 Password: 465480

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
  - a. Approval of Meeting Minutes
- IV. New Business**
  - a. New Products to Market to be reviewed as single products:
    - i. Xepi™ (Antibiotics, Topical)
    - ii. Zeposia® (Multiple Sclerosis Agents)
  - b. New Products to Market to be reviewed along with their respective classes:
    - i. Xcopri™ (Anticonvulsants)
    - ii. Kynmobi™ (Antiparkinson's Agents)
    - iii. Caplyta™ (Antipsychotics)
    - iv. Nexletol™ and Nexlizet™ (Lipotropics, Other)
    - v. Dayvigo™ (Sedative Hypnotics)
- V. Therapeutic Classes with Recommended Changes**
  - a. Alzheimer's Agents
  - b. Anticonvulsants
    - i. Anticonvulsants: First Generation
    - ii. Anticonvulsants: Second Generation (includes new agent Xcopri™)
    - iii. Anticonvulsants: Carbamazepine Derivatives
  - c. Antimigraine Agents, Other (Anti-Migraine: CGRP Inhibitors)
  - d. Antiparkinson's Agents (includes new agent Kynmobi™)
  - e. Antipsychotics
    - i. First-Generation Antipsychotics
    - ii. Second-Generation Antipsychotics (includes new agent Caplyta™)
    - iii. Antipsychotics: Injectable
  - f. Lipotropics, Other (includes new agents Nexletol™ and Nexlizet™)
    - i. Familial Hypercholesterolemia Agents
    - ii. Lipotropics: Bile Acid Sequestrants

- iii. Lipotropics: Cholesterol Absorption Inhibitor
- iv. Lipotropics: Fibrin Acid Derivatives
- v. Lipotropics: Niacin Derivatives
- vi. Lipotropics: Omega-3 Fatty Acids
- vii. Lipotropics: PCSK9s
- g. Neuropathic Pain
- h. PAH Agents, Oral and Inhaled
- i. Sedative Hypnotics (includes new agent Dayvigo™)
- j. Stimulants and Related Agents
  - i. Narcolepsy Agents
  - ii. Stimulants and Related Agents

**VI. Consent Agenda**

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

Angiotensin Modulator Combinations	Beta-Blockers
Angiotensin Modulators	Bladder Relaxant Preparations
Antianginal & Anti-ischemic	BPH Treatments
Antiarrhythmics, Oral	Calcium Channel Blockers
Anticoagulants	Lipotropics, Statins
Antidepressants, Other	Movement Disorders
Antidepressants, SSRIs	Platelet Aggregation Inhibitors
Antidepressants, Tricyclic	Skeletal Muscle Relaxants
Antimigraine Agents, Triptans	Smoking Cessation
Axiolytics	

**VII. Adjournment**

- a. Schedule of Upcoming Meetings
  - i. **November 19, 2020**
- b. Collection of Travel Vouchers

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.